{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019696","form_type":"8-K","ticker":"OFIX","cik":"0000884624","company_name":"Orthofix Medical Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.602944+00:00","generated_at":"2026-06-15T11:23:34.228966+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Orthofix Q1 net sales $175.2M (+65% reported, +12% pro forma CC); GAAP EPS $(1.71), adj. EPS $(0.10)","bullets":["Net loss of $60.9M vs. $4.5M loss prior year; adjusted net loss $3.6M vs. adj. net income $1.0M.","U.S. spinal implant pro forma sales +18% YoY; Bone Growth Therapies +14%; Global Orthopedics +13.6% CC.","Full commercial launch of Lattus Lateral Access System and Fathom Pedicle Retractor System announced.","FY 2023 net sales guidance raised to $750-756M (from $743-753M); adj. EBITDA expected $40-45M.","Cash $50.0M; $45M drawn on $300M revolver; free cash flow $(45.9)M for Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019696","json":"https://secwatch.observer/filing/0000950170-23-019696.json","markdown":"https://secwatch.observer/filing/0000950170-23-019696.md","text":"https://secwatch.observer/filing/0000950170-23-019696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/884624/000095017023019696/0000950170-23-019696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/884624/000095017023019696/ofix-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T11:23:34.228966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19a2430efdbe91727fe3cd3c9e26d04d24b0aa6d","claim":"Orthofix Medical Inc. reported the quarter ended March 31, 2023 results: revenue $175.2 million, net income $(60.9) million, or $(1.71) per share, EPS $(1.71).","evidence_excerpt":"and certain related legal expenses, which are recorded as general and a --- EX-99 (EX-99.1) --- EX-99 Exhibit 99.1 Orthofix Reports First Quarter 2023 Results • Net sales of $175.2 million, an increase of 65% on a reported basis and 12% on a pro forma constant currency basis over prior year • Bone Growth Therapies growth of 14%, with growth coming from both spine","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/884624/000095017023019696/0000950170-23-019696-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$175.2 million"},{"label":"Net income","value":"$(60.9) million, or $(1.71) per share"},{"label":"EPS","value":"$(1.71)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"cc07820dfcc456dca8eb6fcbdd112cc4504aadb0","claim":"Orthofix Medical Inc. reported the year ended December 31, 2023 results: revenue $750 to $756. Guidance reaffirmed.","evidence_excerpt":"changes that may occur this year. Current 2023 Outlook Previous 2023 Outlook (Unaudited, U.S. Dollars, in millions, except per share data) Low High Low High Full year net sales $ 750 1 $ 756 1 $ 743 $ 753 Full year adjusted EBITDA $ 40 $ 45 N/A N/A 1 Represents a year-over-year increase of 62.8% to 64.1% on a reported basis and an increase of 7.0% to 7.9% on a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/884624/000095017023019696/0000950170-23-019696-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$750 to $756"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}